| Literature DB >> 35414478 |
Man Liu1, Gyeoung-Jin Kang1, Samuel C Dudley2.
Abstract
Cardiomyopathies are associated with arrhythmias and cardiac ion channel downregulation. This downregulation is arrhythmogenic. Paradoxically, antiarrhythmic therapies are based on ion channel-blocking drugs that further downregulate these channels and exhibit proarrhythmic risk. Recent studies have shown that inhibition of the protein kinase RNA-like ER kinase (PERK) arm of the unfolded protein response (UPR) prevents select cardiac ion channel downregulation and plays a protective role against arrhythmias. Prevention of ion channel downregulation represents as a novel therapeutic strategy to treat arrhythmias in myocardial infarction and heart failure.Entities:
Keywords: cardiac ion channel; heart failure; mRNA degradation; myocardial infarction; therapy
Mesh:
Substances:
Year: 2022 PMID: 35414478 PMCID: PMC9149111 DOI: 10.1016/j.molmed.2022.03.006
Source DB: PubMed Journal: Trends Mol Med ISSN: 1471-4914 Impact factor: 15.272